Virosomes: A groundbreaking revolution in novel drug delivery

Sreeja C Nair*, Sreelekshmi A S, Aslam Abdul Rahiman C A, Karthik Krishnan, Gopika G, Priyanka Nair T, Unnithan Gauri Ajit

Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi - 682041, Kerala, India

ABSTRACT

The site-specific action of the drug has been seen from the last eras of the revolution in drug delivery technologies. Drug delivery opportunities by the use of biomimetic nanoparticles like virosomes is a stimulating area of research & development as it demonstrates targeted action by fusion with the target cell. Virosomes are vesicular particles reconstituted from viral envelopes which are non-replicating “artificial viruses” that denotes a unique system for presentation of antigen directly into the host cell. Trials have been created to use them as vaccines or adjuvants moreover as a delivery system for medicine, nucleic acids, or genes. Various attempts have been made to use them as vaccines or adjuvants as well as a delivery system for drugs, nucleic acids, or genes as they are biocompatible, biodegradable, non-toxic and non-autoimmunogenic. The production of vaccines increasingly moved away from living attenuated or inactivated whole organisms to safely killed organism. A virus that is safely killed can be a promising vector because it does not cause infection, and the viral structure allows the virosoe to identify different components of its target cells. Pevion’s virus-like particle (VLP) vaccine technology, called virosomes, and its architecture is specifically designed to produce safe and efficient vaccine subunits. Virosome-based vaccination is effective in reliable regulatory and safety records as well as the feasibility of upgrading production and has been approved in more than 40 countries, including infants and older people. The prospect of drug delivery and targeting using virosomes is a vital area of research and development. This review pinpoints the various aspect of virosoe and will be a milestone for the researchers in the field of drug delivery.

INTRODUCTION

Over the past few decades, a crucial quantum leap has been undergone in the area of drug delivery system (DDS). The main drawback of the majority of the potential drugs is a failure to attain targeted action. Certain conditions such as cancer and many neurodegenerative brain disorders require targeted and controlled release actions. Most of the potential drugs are often abandoned during development due to their failure to attain the targeted effect (Nupur et al., 2015). Overall, cancer treatments generally comprise chemotherapy, surgery, and radiation therapy, but limitations bound all three of them. Both radiation therapy, as well as sur-
Vesicular drug delivery systems are promising in the present scenario of drug discovery systems, to overcome the limitation of the drug: lower bioavailability and rapid elimination from the body. The vesicular system plays a significant role in new drug delivery (otherwise known as NDD), particularly in the sorting of a diseased cell, diagnostics, gene and genetic materials, safe, effective and targeted in vivo drug delivery. They function like a system of sustained release and minimise the elimination of rapidly metabolisable drugs. Over the last few decades, they have been extensively used as drug carriers. There are different types of vesicular drug delivery systems such as enzymosomes, virosome, ufasome, cryptosome, emulsosomes, discosomes, aquasomes, genosomes, ethosomes, archaeosomes, hemosomes, vesosomes, proteosomes, erythrosomes, photosomes, cubosomes, collidosomes, layerosomes, erythrosoe etc. The lipid-based drug delivery systems are of four types; they are emulsion-based system, stable-particle lipid system, vesicular system and reliable -lipid tablet system (Aiswarya et al., 2019).

Liposomes, a modern vesicular drug delivery system that can overcome the snag correlated with traditional or conventional drug delivery systems and also they can minimise toxicity associated with drugs. The term liposome is derived from two Greek words: ‘Lipos’ meaning lipid (fat) and ‘Soma’ meaning body. Liposomes are small sac-like structures which contain phospholipids as their monomeric units, and they can be found in a series of sizes with either unilamellar or multilamellar construction. Its name refers to its structural building blocks – the phospholipids, not to its size. Dr Alec D Bangham, who was a haematologist at the Babraham Institute in Cambridge, was the first person to expound details regarding liposomes in the year 1964. Liposomes can be infused using drugs and can be vividly utilised for the transport and delivery of anticancer drugs as well as medications for other diseases also (Daraee et al., 2016). Lipid components have been honed to abtain its consumption by the reticuloendothelial system (RES). The liposomal ability of tissue targeting can be accelerated by manipulating the liposomal surfaces using antibodies or ligands, which are acknowledged by specific cell types. Improve the proficiency of gene delivery by introducing molecules directly into cells, and liposomes have been evolved by collaborating liposomes with fusogenic viral envelope proteins. So, according to the medical definition, a virosome can be defined as “a liposome that has protein or lipid from the envelope of a virus attached to its membrane and that possesses the antigenic properties of the virus”. Liposomes are used for the transport of drugs because of their unique select properties. Industrial applications comprise the use of...
liposomes as drug delivery vehicles in medicine, signal enhancers/carriers in analytical biochemistry and medical diagnostics, immunisation adjuvants, solubilisers for different ingredients as well as support matrices for different ingredients and cosmetic penetration enhancers (Gregoriadis et al., 1987).

DIFFERENCE BETWEEN LIPOSOMES AND VIROSOMES

The difference between the two drug delivery system, virosomes and liposomes are shown in Table 1.

The name virome is derived from two Greek words: ‘Viros’ meaning virus and ‘Soma’ meaning body. Virosomes are a particular class of proteoliposomes. Almeida et al. first prepared virosomes, where they injected distilled spike proteins of influenza into preformed liposomes (Almeida et al., 1975). The most common virus of choice is the influenza virus in which the virosomes obtained are devoid of internal nucleic acid core and genetic information. After that, several viral envelopes have been reconstructed. Examples of viruses used in the preparation of virosomes and their applications (Nupur et al., 2015) are depicted in Table 2.

![Figure 1: Structure of virome](image)

Figure 1: Structure of virome

NECESSITY FOR THE DEVELOPMENT OF VIROSOMES

1. To attain desired targeted action - Virosomal system should be established to prevent systemic adverse effects and to achieve site-specific action.

2. To aid in the delivery of macromolecules and drugs - The most crucial factor in the therapy is the delivery of drugs and macromolecules. Since virosomes have empty inner space, they can be used for macromolecule targeting.

3. Reduce systemic side effects - Targeted action cannot be achieved with the conventional structures, which eventually results in increased toxicity. Viosome production is vital to resolve the factor.

4. To protect the pharmaceutically active substance from proteolytic degradation - Active ingredient degradation typically occurs in the stomach after the oral intake. There is also concern about proteolytics and degradation due to low endosomal pH. Using virosomes can help prevent this problem (Nupur et al., 2015).

Advantages of virosomal drug delivery system

1. Virosomal technology has a high safety profile and is approved by FDA.

2. No chance of transmission of ailments and no auto immunogenicity.

3. Anaphylaxis is absent.

4. They are biocompatible, biologically degradable, and non-toxic.

5. Serves as all vital drugs – antineoplastic agents, proteins, enzymes, peptides, nucleic acids, antibiotics, anti-infection agents, anti-fungals.

6. Facilitates the mixture drive of endolysosomal trajectories.

7. Degradation of drug is prevented. Allow medication to be transmitted into target cell cytoplasm. Defends drugs from corruption.

8. Target targeted antigen distribution and immune response amplification.
Table 1: Difference between virosomes and liposomes

| Virosomes                                      | Liposomes                                      |
|------------------------------------------------|------------------------------------------------|
| More potential to fuse with cells              | little potential to fuse with the cells        |
| Efficiently delivers the encapsulated molecules to the cytoplasm | Fails to deliver encapsulated molecules to the cytoplasm |
| Membrane fusion property is present           | Membrane fusion property is absent            |
| More protection for therapeutical macromolecules from harsh compartmental microenvironment. | Less protection for therapeutical macromolecules from harsh compartmental microenvironment. |
| Macromolecules are protected from proteolytic degradation and low pH. | Proteolytic degradation and low pH affect the macromolecules. |

Table 2: Virus used in virosome production and its applications

| Viruses used for the preparation of virosomes | Applications of virosome                                      |
|---------------------------------------------|---------------------------------------------------------------|
| Semliki Forest virus (SFV)                  | Propagation into membrane vesicles                            |
| Sendai virus                                | Anticancer immune activators and apoptosis inducers           |
| vesicular stomatitis virus (VSV)            | Vehicle of gene transfer to animal cell                       |
| Sindbis virus                               | Hybrid vehicle for efficient and safe drug delivery commonly in cancer treatment |
| Influenza virus                             | Delivery vector for TAAs and TAA-expressing plasmids          |

Table 3: Detection of fusion activity of molecules

| Fusion Molecules                        | Visualization Methods                                      |
|-----------------------------------------|------------------------------------------------------------|
| Biological or artificial target membranes | Fluorescent resonance energy transfer assay (RET).          |
| Indirect method                         | pyrene-labeled lipids                                       |
| In vitro fusion with an excimer         | Hemolytic activity                                          |

9. Drugs have protracted uptake, distribution and elimination in the body.
10. Up-scaling as per normal procedure.
11. Virosome allows standardized vaccine regimen unique to patients.
12. Can be administered through injection or by nasal route (Cusi et al., 2000).

Disadvantage of Virosome

1. Manufacturing problems.
2. They can bring about humoral immune responses as they have surface viral glycoprotein.
3. Prolonged PayLoad.
4. Rapid disintegration.

How to overcome the disadvantage of virosomes

1. Hasty disintegration can be overwhelmed by increasing virosome firmness or by allowing virosomes hit target sites within a short period of administration.
2. Quality control assays can be performed using futuristic methods, and batch variability can be tested.
### Table 4: Evaluation of virosomes

| Parameters                                      | Methods of Evaluation                                                                                                                                 |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Electrical surface potential and surface Ph     | pH touchy tests and estimation of zeta potential.                                                                                                    |
| Vesicle shape and surface morphology            | Freeze break electron microscopy and electron microscopy transmission.                                                                             |
| Phase conduct                                   | Differential checking colorimetry, Freeze crack electron microscopy, Dynamic light scrambling, photon connection spectroscopy, Transmission electron microscopy, laser light diffusion, Zeta sizer, gel avoidance and Gel saturation. |
| Vesicle size and size dispersion                | Differential checking colorimetry, Freeze crack electron microscopy, Dynamic light scrambling, photon connection spectroscopy, Transmission electron microscopy, laser light diffusion, Zeta sizer, gel avoidance and Gel saturation. |
| Percent of free medication                      | Radiolabeling, Protamine accumulation, Gel avoidance and Ion trade chromatography, Mini section centrifugation                                        |
| Animal poisonous quality                        | Observation of survival rates, histology and pathology.                                                                                              |
| Surface charge                                  | Free stream electrophoresis                                                                                                                          |
| Pyrogenicity                                     | Rabbit fever reaction test or Limulus ambeocyte lysate (LAL) test.                                                                                |
| Drug discharge                                  | Diffusion cell/dialysis                                                                                                                              |
| Lamellarity                                      | Small edge x-beam dissipating, Freeze break electron microscopy, 13p-NMR.                                                                            |
| Chemical examination of surface                 | Static auxiliary particle mass spectrometry.                                                                                                         |

3. Application of high-quality products with a protocol for better purification.

4. To overcome payload problems, we can use remote loading techniques.

5. Proper cryoprotectants & lyoprotectants can be used to increase the shelf life.

6. Scale-up problems can be compounded by choosing the right preparation and decontamination process by autoclaving or membrane filtration together with aseptic & validated pyrogen removal LAL test.

7. Narrow therapeutic index drugs can be selected (Kapoor et al., 2013).

### History of Virosomes

Influenza virus belongs to the family orthomyxoviridae (family of RNA viruses). It contains a nucleocapsid with a segmented ssRNA (single-stranded RNA) genome and is protected by a viral envelope. Neuraminidase (NA) and Hemagglutinin (HA) are two types of membrane proteins that are located on the surface of the viral envelope. On the surface of the host cell, sialic acid acts as the receptor to which hemagglutinin binds, and thus virus particles adhere to the host cell. Hemagglutinin is accountable for the fusion of the viral envelope membrane with the membrane of the host cell.

Moreover, in neutral conditions, HA does not cause membrane fusion; its fusion activity only acquires by conformational changes in the acidic environment. Influenza virosose is an artificial liposome constituting influenza membrane proteins and is produced by reconstituting the phospholipids and surface proteins of the influenza virus. On treatment with detergent, the envelope of the influenza virus is first broken down into phospholipids, and the nucleocapsid is removed from the mixture. Surface proteins and phospholipids obtained from viruses present in the influenza virosose are then restored from the combination. An influenza virosose retains its membrane fusion potential because of the presence of hemagglutinin on its surface. Therefore, by integrating them into the virosose, it serves as a diffusion vector to introduce macromolecules into the cytoplasm. Influenza virosomes have strong immunogenicity. Influenza virosomal vaccination produces beneficial levels of influenza-specific antibodies, and an influenza virosose is already approved as an influenza vaccine. Influenza virosomes often show an adjuvant effect when they are co-administered with other antigens; thus, several groups have studied the use of influenza virosomes in antitumor immunity activation (Saga et al., 2013; Almeida et al., 1975).
Virosome Structure

The median diameter of virosomes is 150 nm and are unilamellar spherical vesicles. They possess a well-designed glycoprotein to envelop and the bilayer membrane-phospholipid are insinuated with neuraminidase (NA) and hemagglutinin (HA) as represented in Figure 1. Virosomes are fusion-active vesicles and cannot replicate. By amending the content or form of the lipid membrane, it can be used to achieve the best physiological effect. Depending on the phospholipid incorporated (positive or negative) into the membrane it can be used to generate antisense-oligonucleotide carrier, Tumor-specific monoclonal antibody fragments (Fab) and many peptides, cytokines, and monoclonal antibodies (MAbs) which act as ligands can even be integrated into it. Usually, the used virus is the influenza virus for the production of virosome (Jonge et al., 2006).

VIROSOME FUNCTIONS AND ITS ACTION

Virosomes function both as a conveyor of drugs and also as adjuvant having specific capabilities in the enrollment of a healthy body response. The function of the transporter includes the beneficial influence of incorporation of the antigen into a more exceptional composition that is to the virosomal compound. The resistant mechanism of the virosomes and their segments with the immune energising properties is identified by adjuvant capacity. More than anything, virosomes dominate when it comes to improving particular invulnerability without causing an unspecific aggravation (Schumacher, 2005).

The repeatedly arranged hemagglutinins on the surface of virosome allow fast reaction of immunoglobulin receptors located at B lymphocytes. The dendritic cells (antigen containing cells) absorb the virosomes. The virosomal surface antigens and those obtained through damaged virosomes join the MHC class II pathway, triggering helper T cells. Then antigen accesses the cytosolic MHC class I pathway by fusion of a virosome, activating Cytotoxic T Lymphocytes (CTL). Ligands may be bound to the virosomal surfaces for a specific action, like medications with smaller therapeutic windows (cytotoxic medications) (Germain, 1994).

Virosomes function primarily by two methods:

By encouraging immune reaction

1. Carrier Function
2. Adjuvant Function

By transporting drugs to the site of activity

1. Drug Entrapment
2. Adsorption on Surface of Virosomes (Hukriede et al., 2005)

Encouraging immune reaction

Virosomes function both as a carrier and adjuvant triggering immune reaction. They managed to activate appropriate immunity without any severe inflammation

Carrier Function

The carrier function demonstrates the decisive role of an antigen embedded.

Antigen incorporation into virostone:

1. Keeps native B cell epitope status
2. Improves antigen stability

By transporting drugs to the site of activity

Drug Entrapment

Medication can be lodged within the virosome. They are especially helpful in the supply of genes, nucleic acid, enzymes and peptides etc. The integration of these materials takes place at the time of preparation of the virosome. E.g., the virosomal system has effectively transmitted diphtheria toxin’s gelonin subunit A and ovalbumin to the target cells.

The following steps deliver the active moiety:

Virosome binding to the target cell membrane

1. Cell membrane destruction
2. Cell membrane fusion with virosome bilayer
3. Distribution of virosomal contents inside the cell

**Adsorption on the surface of virosomes**

The pharmaceutically active ingredient is either adsorbed or directly attached using carrier onto the surface of the virosomes.

**METHODS OF PREPARATION OF VIROSOMES**

1. Selection of virosomes
2. Selection of antigen
3. Reconstituted of virosomes

**Selection of virosomes**

Virosomes can be formed by reconstituting its viral envelope from different viruses. While it is possible to create virosomes from Epstein burr- virus, Sendai virus, HIV, Sindbis, herpes simplex virus, Friend murine leukaemia virus, Semliki wood. It is usually made from the influenza virus.

**Antigen selection**

Selection of antigen is according to our needs. This antigen is found in a fungus, carcinogenic cell, bacterium, or whole organism. Components of cells, for example, RNA, plasmid or DNA, can be the antigen. And may also be used as antigen to represent carcinogenic cells, bacterium parasites or entire cells. Once united to the lipid anchor, the antigen can be uploaded into the virosomes.

**Reconstitution of virome**

Detergents (octaglucoside, triton x-100, nonidert p-40) are used to solubilise the virome. When the genetic material and viral internal protein solubilise with the detergent, it is extracted from the supernatant by many diverse methods such as dialysis and hydrophobic resins. Then matrix protein of the virus and nuclei capsid are obtained using the technique of ultracentrifugation. Eighty-two per cent of viral protein and phospholipid can be recuperated. Antigen which is by now joined with lipid anchor can be united with a polymer or surfactant solution, and this is treated with a virome carrier to obtain antigen bound virome (Sharma and Yasir, 2010; Singh et al., 2017).

**CHARACTERISATION OF VIROSOMES**

**Structure and size**

Usually, electron microscopy for the Negative stain will be given to evaluate the fine-structure and size of virosomes. Staining solution of neutral ph can avoid the acid-induced conformational changes of hemagglutinin.

**Protein detection**

Virome preparation is comparatively clear protein to lipid ratios may typically be a result. The agent Sodium dodecyl sulfate-polycrylamide gel electrophoresis (SDS-PAGE) is used to confirm the presence of HA protein in the virosomes.

**Fusion activity**

Regularly, virosomes show combination movement of pH-dependent films such as native cold infections. Combination with a virome and falsified target or organic films can be tracked with an excimer measure (in vitro) using pyrene-named lipids, whereby pyrene phosphatidyl choline-name surface thickness decreases with an unlabeled layer matched to a decline in excimer fluorescence. Additionally, combination action can be tested by determining hemolytic action, which shows comparable pH dependence (Kalra et al., 2013; Singh et al., 2017).

Fusion activity can also be monitored indirectly by determining hemolytic activity which closely resembles fusion activity and reveals a pH dependence identical to that of fusion.

The fusion molecules and their visualisation methods for detecting the fusion activity are portrayed in Table 3.

**EVALUATION OF VIROSOMES**

Evaluation parameters and the methods are illustrated in Table 4 (Shaikh et al., 2018).

**UPTAKE OF VIROSOMES BY CELLS**

The approach of virosomes into the target cells can be divided into four distinct steps:

1. Attachment of virosomes
2. Penetration
3. Functions by the carrier
4. Memory support

**Attachment of virosomes**

This includes binding of virosomes via HA to cell receptors that are glycoprotein or glycolipid membranes with terminal sialic acid. In the case of certain virosomes, the fragments of Fab are integrated into the virosomal surface by a cross-linker with a spacer arm. Besides, certain virosomes will acknowledge antigenic structures on the surface of...
the target cell, resulting in the attachment of two different binding mechanisms to target cells. Different virosomes thus exert selectivity on different types of cells.

**Penetration**

Receptor-mediated endocytosis occurs after attachment of virosomes. The virosomes are caught in the endosome. A viral spike glycoprotein, Hemagglutinin (HA) mediates the acidic fusion of the membrane of virosomes with the membrane of endosomes. This fusion between the membranes of virosomes and endosomes results in the virosomal discharge from their lipid envelope, which in turn provides admittance of the encapsulated drugs to the cytosol.

**Functions by the carrier**

The antigen is balanced by a reconciliation of the antigen to higher structures of molecules of the virosomes, and this safeguards the regional status of the B cell antigenic determinant and protects the antigens from degradation. In expansion, the introduction of the antigen as a monotonous surface structure increases its recognition by counteracting agent producing B cells.

**Memory support**

On interaction with flu-inferred hemagglutinin (HA), a memory reaction is triggered in most of the individuals who may be due to their previous exposure to influenza. This includes both humoral as well as cellular invulnerability. The existing flu-specific antibodies can tag virosomes which are capable of managing the rapid cell-introducing antigen (APC). Also, the memory T cells rapidly multiply to aid in the target-specific delivery of these antigens along with the discharge of cytokines for amplifying the intended immune response (Singh et al., 2017).

**CELL INTERACTION OF VIROSOME**

The virosome innovation’s key favoured point of view is its capacity to imitate and express the in-vivo contamination. This will be beneficial in drawing resistant groups and to organise macromolecules on a separate operation site. The virosomes sense and bind with the very same receptors which are used whenever a common viral disease may occur. One such example is flu-virosomes use corrosive sialic receptors. When the infection has accepted the cell receptor, the mixture of the viral and endosomal layer is observed. When flu virosomes, for example, arise, the viral protein hemagglutinin (HA) utilises its twin to unite for a similar cause.

Additionally, neuraminidase (NA) is incorporated in the virosomal mixture because this can improve the viroson’s immune responses and sensitivity on a particular tissue. The link of viroson receptors has been investigated for the therapy of numerous diseases like parasitic and viral diseases, neurological disorders and many other dysmetabolic problems (Liu et al., 2014). The main point in each of the cases is the marshalling of drug particles, nucleic corrosive or a nano-sized protein to the intended activity site. At the virosomal surface, the proteins and peptides were efficiently mixed with glycoproteins.

**VIROSOMAL DRUG DELIVERY APPROACH**

In the aqueous centre or the lipid bilayer of the virosomes, the biologically active drug compounds may be embedded to promote the incorporation of compounds to the cells. In particular, the virosomes are valuable for the supply of genes or nucleic acids. After virosomal fusion with the endosomes or plasma membrane, such compounds are delivered to the cytoplasm. In the host cells genes or nucleic acids that encode a naturally found protein is added and expressed, ensuring that the sequence of expression contains the relevant regulatory factors for cis action. During the production of virosomes, nucleic acids or drugs are inserted to the virosomes. After elimination of nucleocapsid, the biologically active compound will be added to the solution containing lipid-HA.

Additionally, the biologically active compound is first introduced into the liposomes then it is combined with two hemagglutinins embodied viroson having specific pH levels to create a hybrid of viroson and liposome. Proteins are also transmitted via viroson into cells. Example, virosomes has successfully delivered the diphtheria toxin’s gelonin subunit A and ovalbumin into the targeted cells. The access gained by the encapsulated peptides and proteins to the cytoplasm is indicated by the virosomes bearing influenza nucleoprotein derived peptides or intact ovalbumin mediated robust cytotoxic T lymphocyte responses (Bungener et al., 2005).

**Antisence-L-myc-virosomes**

Inside the viroson, the antisense-L-myc-phosphorothioate oligodeoxyribonucleotides were enclosed. In the Small Cell Lung Cancer (SCLC) cell lines like H82, H209 AND H510 the antiproliferative effects of virosonal-embodied L-myc antisense DNA were assessed. Antisense-L-myc virosomes were applied to human SCLC cell lines which expressed, resulting in robust concentration-dependent inhibition of thymidine incorporation. Virosomes entrapped random-order OPT, and L-myc OPT only has minor consequences on the thymidine absorption (Waelti and Glück, 1998).
ADMINISTRATION OF VIROSOMES

Virosomes can be delivered via parenterally, orally, topically and transdermally, the main parenteral routes include intravenous, subcutaneous, intramuscular, inhalable and intrathecal delivery (Daemen et al., 2005). These are usually maintained in buffered saline that is 135-150mM NaCl, but there are also other appropriate solvents available. Such formulations should be purified by traditional techniques of liposomal sterilisation, including membrane filtration. They should contain auxiliary substances like isotonicity controlling agents and buffering agents such as calcium chloride, potassium chloride, sodium chloride, and sodium lactate and sodium acetate to imitate physiological status. Virosomal concentrations of 20 to 200mg/ml is used in the solvent, and this can be tailored for the function per standard. The virosomes can be integrated into implantables for the initiation of long term treatment (Rathore and Swami, 2012).

LOOKING AHEAD

Virosomes are a new revolutionary advanced drug transport system for bioactive substances, but the genes and nucleic acids, in particular. The virosomal surface can be adjusted appropriately to allow the proper transport of drugs to the targeted site. Yet detailed pharmacokinetic profile, bioavailability, clinical impacts and protection are required and the stability studies to be extensively covered to establish long-term efficiency as a reliable, secure and inexpensive method of targeting and delivering drugs. In the cells of insects, Ebola virosomes were developed with a recombinant baculovirus expression vector system, and its effectiveness against Ebola Virus Disease was examined in mice. Virosome immunisation of mice provided full immunity against Ebola infection for vaccinated mice (Sun et al., 2010). The virosomes are, therefore, an essential instrument in the production and manufacture of vaccines. Further evaluation can also help to establish virosomes for coronavirus in future.

APPLICATIONS OF VIROSOMES

Viruses conduct intracellular parasites, although for their survival they are necessarily subordinate to different host cells. This guidance brings in the creation of a system for the conveyance of medication that copies the cell disease viral example. Virosomes area unit is created from a lipid bilayer with the infective agent surface glycoproteins enlarging from the surface of those vesicles. This vesicular layer synthesis makes the virosomes biologically compatible and biologically degradable. These are ingested productively and are sorted to the external site devoid of changing the biological procedures.

Further, the virosoome plan and arrangement are in a way that medicinal particles of different type can be used in it. The lipid bilayer will assimilate the hydrophobic medicines into it effortlessly. Conversely, hydrophilic medications transform into a fragment of the focal lacunae.

Virosomes is also paired with an immune reaction to assure the tissue-specificity-focused conveyance of a useful operator. These antibodies bind to the different cell receptors that enable the transfer of drug atoms to these targets. Notably, this property can be used to convey the drug particles with minimal safety profiles. For example, anticancer drugs will be transmitted particularly to tumours by marking the virosomes with antibodies. The United States Food and Drug Administration (FDA) has approved numerous virosoome-based products for human use. Virosomes have shown that macromolecules, including drugs, nucleic acids and proteins, have been transferred viable to different types of cells counting hepatocytes, healthy cells, erythrocytes and glioma cells. Virosomes that include malignant neoplastic drugs, malaria drugs, bacterial, and fungal operators have shown to be efficient in vitro and in vivo discharge profiles (Sharma and Yasir, 2010). The surface glycoproteins of contam-ination, liver disease infections and stomatitis infection are integrated with success in numerous protein and drug transport systems.

Bacterial apparitions were produced in light of the same norm. Such vesicles embody the outer shell or the supermolecule of various gram-negative microscopic organisms. Such bacterial appearances mimic a proportional pattern as we can witness in case of some distinctive illness. In any case, the virosoome-based sedate conveyance is fast, sheltered and viable, rather than any other related device.

As immunopotentiating mediators

Virosomes are the molecules that can serve the purpose of providing antigens and drugs to particular types of cells. The principal property exploited by virosoome architecture is the cooperation with the virus substance proteins and therefore the cellular receptors. Besides, the recognition, uptake and illustration of the antigen introduced by the specific antigen-presenting cells into the virosoome help to activate the immune system. As a consequence, effective immune responses to the regulatory and the effector are produced. Both cell-mediated and immune system humoral alarms and cell-mediated alarms are activated.

Besides, both cytotoxic and helper-T-cell responses
are caused by virosomes. Virosomes might not solely function a way of sending the immunising agent to the body, however, may additionally act as adjuvants to direct the immunologic response to the substance in question. They can quickly attract the nerve fibre cells and different matter presenting cells to achieve medical speciality edges, being of a particular kind. The structure of the virosome ensures that the antigen is continually transmitted to the immune system, whether it is inter-related to the lipid bilayer, conjugated to the surface proteins or exist in the central cavity. The delay in the release of the matter can function a way to concentrate the response to the precise matter for a depot-like impact to be achieved. Excessive immune defence against varied diseases can be achieved by combining the delivery of both antigen and the adjuvant. Recent studies of murine models showed up to fourfold higher body substance response within the case of a viroson-based product compared to that determined within the case of the delivery of the aborning substance. Additionally, the combined delivery of antigen and adjuvant can assist in achieving an excessive immune defence against various diseases (Radha et al., 2013; Singh et al., 2017). While comparing the delivery of nascent antigen and the product based on virosome, the murine models have shown fourfold humoral responses in modern studies.

As targeted drug delivering negotiators

Drugs should be altered or wrapped in a way so that restoratively real amount of drug atoms enter the specific site where the action is needed. Change may comprise modification of the medication’s physical as well as synthetic parameters resulting in the creation of new elements, and other product components can be mixed to change their in vivo profiles or, sometimes can modifying the physical structures of the drug particles. It can package naturally occurring medicines into themselves. In the focal compartment, the water-seeking medications are prepared amid the virosome generation. Then again the fat-soluble drugs cannot be epitomised in this way, and are built in the lipid bilayer along these lines.

As a method of transporting these medical particles to the probable spot of operation, virosomal disintegration may take place within the cell. In various tests, the exemplification of diverse types of genetic material in the virosome to be used for prophylactic or beneficial purposes was achieved. The virosome’s lipide bilayer makes a distinction in reassuring these remedial operators of different nucleic corrosive corrupting proteins like DNAsases and RNAAsases (Soussan et al., 2011). After perceiving the specific cell types, the viral glycoproteins aid in the film mix. When expressed, the inherited content can then be used by the cell hardware to establish the encoded qualities.

In gene therapy

A low PH-dependent fusion reaction between the limiting membrane of the endosomal cell compartment and the viral envelope is controlled by hemagglutinin which is followed by cell-by-cell receptor endocytosis intake of the virus particles (Nupur et al., 2015).

In RNA and DNA

The synthesis of newly induced and constitutively conveyed protein and recently induced protein can be successfully reduced by encapsulating small interfering RNA in virosomes, and this can overcome the shortage of suitable methods of delivery. Virosome triggered with SiRNA via Intraperitoneal route can lead to the delivery of nucleotides to peritoneal cells (Muhammad et al., 2012).

In malarial therapy

Virosomes represents a revolutionary method for delivery of drugs for various bioactive molecules, particularly for genes, nucleic acid and for other numerous indications. Virosomal surfaces can be adequately revised to allow targeted drug delivery. Antimalarial peptide formulated virosomes demonstrate strong permissibility and great adaptive immune response in humans. NPNA region and the AMA-1 merozoite are the two peptide region identified which can serve as an antigen for the malarial vaccine (Miyanohara, 2012).

In cancer treatment

Virosomes have also been used in oncology to bring peptides referring to tumours injected with antigens, such as peptides from parathyroid hormone-related proteins or recombinant proteins such as her -2 neu Fab combined anti-Fab – doxovirosomes combined the anti-proliferate properties of monoclonal antibodies with the cytotoxic activity of doxorubicin in vivo (Bhattacharya and Mazumder, 2011).

CONCLUSION

The virosomal drug delivery system is an intelligent approach for targeted delivery of drugs and several other biologically active molecules, particularly nucleic acids or genes. The main motive behind the development of virosomal technique is to overcome the limitation of inadequate drug delivery towards targeted cells, tissues and organs of the body. Virosomes are biodegradable, non-
poisonous, biocompatible and non-auto immunogenic unilamellar phospholipid bilayer vesicles that comprise proteins derived from viruses. Antigens can be delivered to the host body using various routes of administration like intradermal, intramuscular and intranasal route, depending upon the aim of immunisation. Virosomes are considered as an effective prophylactic and therapeutic agent due to their added advantage of tissue targeting immune activation & potentiation over other targeted drug delivery systems. Hence, they can be widely used in the field of cancer therapy as a carrier for immunomodulating molecules as well as for targeted drugs. Application of Virosome in the field of targeted drug delivery system will bring a new opportunity & also open a new era in the modern pharmaceutical sector & human life too.

ACKNOWLEDGEMENT

We are immensely obliged and thankful to Dr Sabitha M, Principal, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India. We also extend our gratitude to the Department of Pharmaceutics and all other faculties for catering legitimate facilities and guidance for our work.

Conflict of Interest

The authors declare that they have no conflict of interest for this study.

Funding Support

The authors declare that they have no funding support for this study.

REFERENCES

Aiswarya, M. U., Raju, K., Menon, R. B., Lakshmi, V. S., Nair, S. C. 2019. Cryptosomes: a revolutionary breakthrough in novel drug delivery. International Journal of Applied Pharmaceutics, 11(1):7–13.

Almeida, J. D., Edwards, D. C., Brand, C. M., Heath, T. D. 1975. Formation of virosomes from influenza subunits and liposomes. The Lancet, 306(7941):899–901.

Bhattacharya, S., Mazumder, B. 2011. Virosomes: A Novel Strategy for Drug Delivery and Targeting. Bio Pharm International, 24(1):9–14.

Bungener, L., Huckriede, A., de Mare, A., de Vries-Idema, J., Wilschut, J., Daemen, T. 2005. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine, 23(10):1232–1241.

Cusi, M. G., Zurbriggen, R., Valassina, M., Bianchi, S., Durrer, P., Valensin, P. E., Donati, M., Glück, R. 2000. Intranasal Immunization with Mumps Virus DNA Vaccine Delivered by Influenza Virosomes Elicits Mucosal and Systemic Immunity. Virology, 277(1):111–118.

Daemen, T., Demare, A., Bungener, L., Dejonge, J., Huckriede, A., Wilschut, J. 2005. Virosomes for antigen and DNA delivery. Advanced Drug Delivery Reviews, 57(3):451–463.

Daraei, A. H., Etemadi, M., Kouhi, Alimirzalu, A. S., Akbarzadeh 2016. Application of liposomes in medicine and drug delivery. Nanomedicine, and Biotechnology, 44(1):381–391.

Germain, R. N. 1994. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell, 76(2):287–299.

Gregoriadis, G., Davis, D., Davies, A. 1987. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine, 5(2):145–151.

Hukriede, A., Bungener, L., Holtrup, M. 2005. The virosoome concept for influenza vaccines. Vaccine, 23:1–38.

Jonge, J. D., Schoen, P., terVeer, W., Stegmann, T., Wilschut, J., Huckriede, A. 2006. Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1758(4):527–536.

Kalra, N., Dhanya, V., Saini, V., Dr, Jeyabalan, G. 2013. Virosomes: As a drug delivery carrier. American Journal of Advanced Drug Delivery, 3(5):143–147.

Kamper, A. R., Amacker, M., Rasi, S., Westerfeld, N., Gremion, C., Neuhaus, D., Zurbriggen, R. 2007. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine, 25(41):7065–7074.

Kapczynski, D. R., Tumpey, T. M. 2003. Development of a Virosome Vaccine for Newcastle Disease Virus. Avian Diseases, 47(3):578–587.

Kapoor, D., Vyas, R. B., Lad, C., Patel, M. 2013. A multipurpose and novel carrier for drug delivery and targeting - virosomes. Journal of Drug Delivery and Therapeutics, 3(5):143–147.

Liu, H., de Vries-Idema, J., ter Veer, W., Wilschut, J., Huckriede, A. 2014. Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing. Medical Microbiology and Immunology, 203(1):47–55.

Miyahara, A. 2012. Preparation of vesicular stomatitis virus-G (VSV-G) conjugate and its use in gene transfer. Cold Spring Harb Protocol, 2012(4):453–456.
Muhammad, A., Champeimont, J., Mayr, U. B., Lubitz, W., Kudela, P. 2012. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. *Expert Review of Vaccines, 11*(1):97–116.

Nupur, A., Inamdar, Pulgamwar, G. V., Kalyani, A., Jadhav 2015. Virosomes: New frontier for targeting drugs and biological molecules. *Asian Journal of Pharmaceutical Technology & Innovation, 3*(12):92–103.

Radha, G. V., Rani, T., Sarvani, B. 2013. A review on proniosomal drug delivery system for targeted drug action. *Journal of Basic and Clinical Pharmacy, 4*(2):42–48.

Rathore, Swami, G. 2012. Virosomes: a novel vaccination technology. *IJPSR, 3*(10):3591–3597.

Saga, K., Kaneda, Y., BioMed Research International 2013. Virosome presents multimodel cancer therapy without viral replication. 2013:1–9.

Schumacher, R. 2005. Adjuvance of influenza virosomes in CTL induction in vitro. Faculty of Science, University of Basel, Switzerland.

Shaikh, S. N., Raza, S., Ansari, M. A., Khan, G. J. 2018. Athar, GHMD, Overview on virosomes as a novel carrier for drug delivery. *Journal of Drug Delivery and Therapeutics, 8*(6):429–434.

Sharma, Yasir, M. 2010. Virosomes: A Novel Carrier for Drug Delivery. *International Journal of Pharma Tech Research, 2*(4):2327–2339.

Singh, N., Gautam, S. P., Kumari, N., Kaur, R., Kaur, M. 2017. Virosomes as Novel drug delivery System: An Overview. *PharmaTutor, 5*(9):47–55.

Soussan, E., Cassel, S., Blanzat, M., Rico-Lattes, I. 2011. Drug delivery by softmatter: matrix and vesicular carriers. *Angew Chem Int Ed Engl, 48*(2):274–288.

Sun, Y., Jr, C. R., Ye, L., *et al.* 2010. Protection against lethal challenge by Ebola virus-like particles produced in insect cells, 399(1):186.

Waelti, E. R., Glück, R. 1998. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). *International Journal of Cancer, 77*(5):728–733.

Zinkernagel, R. M. 2001. Regulation of the Immune Response by Antigen. *Science, 293*(5528):251–253.